{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T04:26:04Z","timestamp":1793939164172,"version":"4.8.0"},"reference-count":12,"publisher":"American Society of Hematology","issue":"23","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,5]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Quantitative immunoprecipitation mass spectrometry (QIP-MS) allows the identification of the M-protein in patients with multiple myeloma (MM) otherwise in complete response, and could be considered suitable for measurable residual disease (MRD) evaluation in peripheral blood. In the context of the GEM2012MENOS65 and GEM2014MAIN trials, we compared the performance of QIP-MS in serum with next-generation flow (NGF) cytometry in bone marrow to assess MRD in paired samples obtained postinduction, transplant, consolidation and after 24 cycles of maintenance. At each time point, both NGF and QIP-MS were able to segregate 2 groups of patients with significantly different progression-free survival; when the evolution of the results obtained with either method was considered, maintaining or converting to MRD negativity was associated with longer survival, significantly better when compared with sustaining or converting to MRD positivity. Reemergence of MRD by QIP-MS was associated with high risk of imminent clinical progression. In conclusion, MRD evaluation by NGF and MS achieves similar prognostic value based in single time point assessments and kinetics. Thus, the minimally invasive nature of MRD monitoring by MS represents a breakthrough in highly sensitive response assessment in MM. The trials were registered at www.clinicaltrials.gov as #NCT01916252 (GEM2012MENOS65) and at EudraCT as #2012-005683-10; and as #NCT02406144 (GEM2014MAIN) and at EudraCT as 2014-00055410.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2024024995","type":"journal-article","created":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T20:18:37Z","timestamp":1726690717000},"page":"2432-2438","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":29,"title":["Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma"],"prefix":"10.1182","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7535-3861","authenticated-orcid":false,"given":"Noem\u00ed","family":"Puig","sequence":"first","affiliation":[{"name":"1Hematology Department, IBSAL, Instituto de Biolog\u00eda Molecular y Celular del C\u00e1ncer-Consejo Superior de Investigaciones Cient\u00edficas, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer, Hospital Universitario de Salamanca, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2920-0327","authenticated-orcid":false,"given":"Cristina","family":"Agull\u00f3","sequence":"additional","affiliation":[{"name":"2Clinical Biochemistry Department, Hospital Universitario de Salamanca, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2264-7791","authenticated-orcid":false,"given":"Teresa","family":"Contreras","sequence":"additional","affiliation":[{"name":"2Clinical Biochemistry Department, Hospital Universitario de Salamanca, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5851-3720","authenticated-orcid":false,"given":"Mar\u00eda-Teresa","family":"Cedena","sequence":"additional","affiliation":[{"name":"3Hospital Universitario 12 de Octubre, Complutense University, i+12, Centro Nacional de Investigaciones Oncol\u00f3gicas, Centro de Investigaci\u00f3n Biom\u00e9dica en Red (CIBERONC), CB16\/12\/00369, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7908-0063","authenticated-orcid":false,"given":"Joaqu\u00edn","family":"Mart\u00ednez-L\u00f3pez","sequence":"additional","affiliation":[{"name":"3Hospital Universitario 12 de Octubre, Complutense University, i+12, Centro Nacional de Investigaciones Oncol\u00f3gicas, Centro de Investigaci\u00f3n Biom\u00e9dica en Red (CIBERONC), CB16\/12\/00369, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6804-2221","authenticated-orcid":false,"given":"Albert","family":"Oriol","sequence":"additional","affiliation":[{"name":"4Institut Catal\u00e0 d'Oncologia, Institut Josep Carreras, Hospital Germans Trias I Pujol, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda-Jes\u00fas","family":"Blanchard","sequence":"additional","affiliation":[{"name":"5Hematology Department, Hospital Ram\u00f3n y Cajal, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8193-1402","authenticated-orcid":false,"given":"Rafael","family":"R\u00edos","sequence":"additional","affiliation":[{"name":"6Hospital Puerta de Hierro, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6372-1970","authenticated-orcid":false,"given":"Mar\u00eda-Bel\u00e9n","family":"\u00cd\u00f1igo","sequence":"additional","affiliation":[{"name":"7Hospital Cl\u00ednico San Carlos, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1238-6970","authenticated-orcid":false,"given":"Anna","family":"Sureda","sequence":"additional","affiliation":[{"name":"8Institut Catal\u00e1 d'Oncologia-l'Hospitalet, Instituto de Investigaci\u00f3n Biom\u00e9dica de Bellvitge, Universitat de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1984-4839","authenticated-orcid":false,"given":"Sunil","family":"Lakhwani","sequence":"additional","affiliation":[{"name":"9Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8354-768X","authenticated-orcid":false,"given":"Javier","family":"de la Rubia","sequence":"additional","affiliation":[{"name":"10Hematology Department, University Hospital La Fe and School of Medicine and Dentistry, Catholic University of Valencia, CIBERONC CD16\/12\/00284, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5493-6707","authenticated-orcid":false,"given":"Ver\u00f3nica","family":"Gonz\u00e1lez-Calle","sequence":"additional","affiliation":[{"name":"1Hematology Department, IBSAL, Instituto de Biolog\u00eda Molecular y Celular del C\u00e1ncer-Consejo Superior de Investigaciones Cient\u00edficas, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer, Hospital Universitario de Salamanca, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6248-2549","authenticated-orcid":false,"given":"Valent\u00edn","family":"Caba\u00f1as","sequence":"additional","affiliation":[{"name":"11Hospital Universitario Virgen de la Arrixaca, IMIB, Murcia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0359-7191","authenticated-orcid":false,"given":"Luis","family":"Palomera","sequence":"additional","affiliation":[{"name":"12Hospital Cl\u00ednico Universitario Lozano Blesa, Zaragoza, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9080-1466","authenticated-orcid":false,"given":"Jos\u00e9-Mar\u00eda","family":"Moraleda","sequence":"additional","affiliation":[{"name":"11Hospital Universitario Virgen de la Arrixaca, IMIB, Murcia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6739-3916","authenticated-orcid":false,"given":"Joan","family":"Bargay","sequence":"additional","affiliation":[{"name":"13Hospital Son Llatzer, Palma de Mallorca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8003-9664","authenticated-orcid":false,"given":"Sergio","family":"Castro","sequence":"additional","affiliation":[{"name":"2Clinical Biochemistry Department, Hospital Universitario de Salamanca, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2534-9239","authenticated-orcid":false,"given":"Laura","family":"Rosi\u00f1ol","sequence":"additional","affiliation":[{"name":"14Hospital Clinic, Institut d'Investigacions Biom\u00e9diques August Pi I Sunyer, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4563-3405","authenticated-orcid":false,"given":"Joan","family":"Blad\u00e9","sequence":"additional","affiliation":[{"name":"14Hospital Clinic, Institut d'Investigacions Biom\u00e9diques August Pi I Sunyer, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9183-4857","authenticated-orcid":false,"given":"Jes\u00fas F.","family":"San-Miguel","sequence":"additional","affiliation":[{"name":"15Cl\u00ednica Universidad de Navarra, Cl\u00ednica Universitaria de Navarra, Centro de Investigaci\u00f3n M\u00e9dica Aplicada, Instituto de Investigaci\u00f3n Sanitaria de Navarra, CIBERONC CB16\/12\/00369, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3393-9570","authenticated-orcid":false,"given":"Juan-Jos\u00e9","family":"Lahuerta","sequence":"additional","affiliation":[{"name":"16Instituto de Investigaci\u00f3n del Hospital Universitario 12 de Octubre, CIBERONC, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1977-3815","authenticated-orcid":false,"given":"Bruno","family":"Paiva","sequence":"additional","affiliation":[{"name":"14Hospital Clinic, Institut d'Investigacions Biom\u00e9diques August Pi I Sunyer, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2390-1218","authenticated-orcid":false,"given":"Mar\u00eda-Victoria","family":"Mateos","sequence":"additional","affiliation":[{"name":"1Hematology Department, IBSAL, Instituto de Biolog\u00eda Molecular y Celular del C\u00e1ncer-Consejo Superior de Investigaciones Cient\u00edficas, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer, Hospital Universitario de Salamanca, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"11","key":"2024120516204387300_bib1","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1182\/bloodadvances.2021006762","article-title":"Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma","volume":"6","author":"Puig","year":"2022","journal-title":"Blood Adv"},{"issue":"2","key":"2024120516204387300_bib2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41408-022-00624-6","article-title":"Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 \/07LT)","volume":"12","author":"Dispenzieri","year":"2022","journal-title":"Blood Cancer J"},{"issue":"10","key":"2024120516204387300_bib3","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1200\/JCO.20.01814","article-title":"Evaluation of sustained minimal residual\u00a0disease negativity with daratumumab-combination regimens in relapsed and\/or refractory multiple myeloma:\u00a0analysis of POLLUX and CASTOR","volume":"39","author":"Avet-Loiseau","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2024120516204387300_bib4","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.2020010439","article-title":"Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE","volume":"139","author":"San-Miguel","year":"2022","journal-title":"Blood"},{"issue":"16","key":"2024120516204387300_bib5","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1182\/blood.2019000241","article-title":"Bortezomib,\u00a0lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma","volume":"134","author":"Rosi\u00f1ol","year":"2019","journal-title":"Blood"},{"issue":"18","key":"2024120516204387300_bib6","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1182\/blood.2022019531","article-title":"Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma","volume":"142","author":"Rosi\u00f1ol","year":"2023","journal-title":"Blood"},{"issue":"10","key":"2024120516204387300_bib7","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"issue":"8","key":"2024120516204387300_bib8","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"6","key":"2024120516204387300_bib9","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1158\/1078-0432.CCR-23-2767","article-title":"Monitoring minimal residual disease in patients with multiple myeloma by targeted tracking serum M-protein using mass spectrometry (EasyM)","volume":"30","author":"Fan","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2024120516204387300_bib10","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/clinchem\/hvz041","article-title":"Mass spectrometry for identification, monitoring, and minimal residual disease detection of M-proteins","volume":"66","author":"Zajec","year":"2020","journal-title":"Clin Chem"},{"issue":"2","key":"2024120516204387300_bib11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41408-021-00418-2","article-title":"Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation","volume":"11","author":"Derman","year":"2021","journal-title":"Blood Cancer J"},{"issue":"1","key":"2024120516204387300_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-022-00772-9","article-title":"Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma","volume":"13","author":"Mai","year":"2023","journal-title":"Blood Cancer J"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/23\/2432\/2319031\/blood_bld-2024-024995-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/23\/2432\/2319031\/blood_bld-2024-024995-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T16:20:51Z","timestamp":1733415651000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/144\/23\/2432\/517879\/Measurable-residual-disease-by-mass-spectrometry"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":12,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2024,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024024995","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,5]]}}}